title: The Carpentier-Edwards supra-annular porcine bioprosthesis: clinical performance to 8 years of a new generation porcine bioprosthesis.
abstract: The Carpentier-Edwards supra-annular porcine bioprosthesis has been utilized at the University of British Columbia since its introduction in 1982. The prosthesis was designed to improve hemodynamics with the supra-annular configuration and to reduce tissue failure with low-pressure glutaraldehyde preservation of the porcine aortic tissue. The prosthesis was inserted in 1,956 patients with 2,129 prostheses between 1982 and 1989. The mean age of the patient population was 62.7 years (range 13 to 87 years). The mean follow-up was 3.7 years per patient. The freedom from thromboembolism and antithromboembolic therapy-related hemorrhage at 8 years was 92% for aortic valve replacement (AVR), 83% for mitral valve replacement (MVR), and 92% for multiple valve replacement (MR) (p less than 0.05, AVR greater than MR greater than MVR). The freedom from structural valve deterioration was 86% for AVR, 73% for MVR, and 96% for MR at 8 years (p less than 0.05, AVR greater than MR greater than MVR). The freedom from nonstructural valve dysfunction and prosthetic valve endocarditis was not different between positions (p = NS). The freedom from valve-related mortality at 8 years was 98% for AVR, 94% for MVR, and 98% for MR (p less than 0.05, AVR greater than MR greater than MVR). The freedom from residual morbidity was not different at 8 years (p = NS). The freedom from treatment failure (valve-related mortality and residual morbidity) was 96% for AVR, 89% for MVR, and 94% for MR (p less than 0.05, AVR greater than MVR greater than MR).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Vancouver General Hospital, Canada.
authors.forename: W R
authors.initials: WR
authors.lastname: Jamieson
authors.forename: R T
authors.initials: RT
authors.lastname: Miyagishima
authors.forename: A I
authors.initials: AI
authors.lastname: Munro
authors.forename: L H
authors.initials: LH
authors.lastname: Burr
authors.forename: M T
authors.initials: MT
authors.lastname: Janusz
authors.forename: H
authors.initials: H
authors.lastname: Ling
authors.forename: R I
authors.initials: RI
authors.lastname: Hayden
authors.forename: H
authors.initials: H
authors.lastname: Tutassaura
authors.forename: A N
authors.initials: AN
authors.lastname: Gerein
authors.forename: J
authors.initials: J
authors.lastname: MacNab
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve; D001705:Bioprosthesis; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve; D012086:Reoperation; D013997:Time Factors